Ignite Creation Date:
2024-05-05 @ 10:15 PM
Last Modification Date:
2024-10-26 @ 10:16 AM
Study NCT ID:
NCT01069575
Status:
COMPLETED
Last Update Posted:
2019-03-19
First Post:
2010-02-16
Brief Title:
Safety Study of Peptide Cancer Vaccine To Treat HLA-A24-positive Advanced Non-small Cell Lung Cancer
Sponsor:
Shiga University
Organization:
Shiga University
Study Overview
Official Title:
Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A24 URLC10CDCA1KIF20A in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety tolerability immune response and clinical efficacies of HLA-A2402 restricted epitope peptides URLC10 CDCA1 and KIF20A emulsified with Montanide ISA 51 for advanced non-small cell lung cancers
Detailed Description:
The investigators previously identified three novel HLA-A2402-restricted epitope peptides which were derived from three cancer-testis antigens URLC10 CDCA1 and KIF20A as targets for cancer vaccination against lung cancer In this phase I trial the investigators examine using a combination of these three peptides the safety immunogenicity and antitumor effect of vaccine treatment for HLA-A2402-positive advanced non-small cell lung cancer patients who failed to standard therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UMIN000003189 | OTHER | UMIN | None |